Ocugen, Inc. to Participate in Fireside Chat at the Cantor Virtual Global Healthcare Conference
September 23 2021 - 3:08PM
Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company
focused on discovering, developing, and commercializing gene
therapies to cure blindness diseases and developing a vaccine to
fight COVID-19, today announced that its Chairman, CEO, and
Co-Founder, Dr. Shankar Musunuri, will present at the 2021 Cantor
Virtual Global Healthcare Conference on Tuesday, September 28, 2021
at 8 a.m. Eastern Time. Dr. Musunuri will discuss COVAXIN™, the
investigational COVID-19 vaccine which the company is co-developing
with Bharat Biotech for the U.S. and Canadian markets. He will also
present information about Ocugen’s breakthrough modifier gene
therapy platform, which has generated product candidates that are
expected to enter Phase 1/2a clinical trials in ophthalmic disease
states over the next 18 months.
The fireside chat can be viewed live at
https://wsw.com/webcast/cantor12/ocgn/2072070 and will be
available within Ocugen’s Investor Relations page found at
https://ir.ocugen.com.
About Ocugen, Inc.Ocugen, Inc. is a
biopharmaceutical company focused on discovering, developing, and
commercializing gene therapies to cure blindness diseases and
developing a vaccine to save lives from COVID-19. Our breakthrough
modifier gene therapy platform has the potential to treat multiple
retinal diseases with one drug — “one to many,” and our novel
biologic product candidate aims to offer better therapy to patients
with underserved diseases such as wet age-related macular
degeneration, diabetic macular edema, and diabetic retinopathy. We
are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for
COVID-19 in the U.S. and Canadian markets. For more information,
please visit www.ocugen.com.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, which are subject to risks and uncertainties.
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “proposed,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should” or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements. Such
statements are subject to numerous important factors, risks and
uncertainties that may cause actual events or results to differ
materially from our current expectations, such as risks and
uncertainties regarding market and other conditions and the timing
of our planned clinical trials. These and other risks and
uncertainties are more fully described in our periodic filings with
the Securities and Exchange Commission (the “SEC”), including the
risk factors described in the section entitled “Risk Factors” in
the quarterly and annual reports that we file with the SEC. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. Except as required by
law, we assume no obligation to update forward-looking statements
contained in this press release whether as a result
of new information, future events or otherwise, after the date
of this press release.
Ocugen Contact: Ken InchaustiHead,
Investor Relations & CommunicationsIR@Ocugen.com
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2024 to May 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From May 2023 to May 2024